Each single-dose vial of Esmolol injection, which is available in 100 mg/10 ml, consists of Esmolol hydrochloride IP, equivalent to 10 mg/ml, along with other ingredients.
Usage of this drug is indicated in the treatment of hypertension, Supraventricular tachycardia, and ventricular rate in case of patients with atrial fibrillation or atrial flutter, in the case of postoperative tachycardia or arrhythmias.
A mild to moderate range of side effects has been observed. Side effects such as dizziness, fatigue, nausea, headache, severe weakness, bradycardia, dryness of mouth, abdominal pain, anorexia, musculoskeletal pain, irritation around the infusion site, thrombophlebitis, inflammation around the injection site region, chill bites, inflammation around the injection site region, chills, and pyrexia.
This medication is to be prescribed cautiously in patients with first- or second-degree heart block, diabetes mellitus, myasthenia gravis, peripheral vascular disease or disorders, hyperthyroidism, hypoglycemia, severe renal dysfunction, pregnancy, or lactation.
This medication is contraindicated in patients with second or third-degree heart block, atrioventricular failure, severe sinus bradycardia, pulmonary hypotension, severe hypotension, phaeochromocytoma, metabolic acidosis, or a prior history of hypersensitivity to Esmolol or any of its constituents.
Dosage and administration
In adults in case of Hypertension or postoperative tachycardia for immediate control initial bolus of 80 mg (~1 mg/kg) over 30 seconds then further 0.15 to 0.3 mg/kg/min via intravenous infusion.For gradual control postoperatively, a loading dose of 0.5 mg/kg intravenously over 1 minute, then further 0.05 mg/kg / min for 5 minutes, if still inadequate response, a second loading dose should be given accordingly.
We have also established roots and begun this new venture in other countries as well, such as Niue, New Zealand, the USA, China, Greenland, Slovakia, Croatia, and Ukraine.